NVO Novo Nordisk A/S

49.78
+0.12  (+0%)
Previous Close 49.66
Open 49.82
Price To Book 15.13
Market Cap 119065806849
Shares 2,391,840,234
Volume 660,060
Short Ratio 3.02
Av. Daily Volume 1,596,459

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Regulatory filing due 1Q 2019.
Semaglutide - oral - PIONEER
Type 2 diabetes
Phase 3 data estimated 1Q 2019.
Concizumab - explorer
Hemophilia A
Approval announced August 25, 2017.
Victoza (liraglutide)
Type 2 diabetes
Approved September 29, 2017.
Fiasp (fast-acting insulin aspart)
Type 1 and type 2 diabetes
Phase 3 trial to be initiated 2Q 2019.
Somapacitan
Growth Hormone Deficiency (GHD)
Phase 2 data due 2Q 2019.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
Approval announced December 5, 2017.
Semaglutide
Type 2 diabetes
Approval announced May 31, 2017.
Nonacog beta pegol
haemophilia B
FDA Approval announced February 19, 2019.
N8-GP
Hemophilia A
Phase 2 data due 4Q 2019.
LAI287
Type 2 diabetes
Phase 2 trial to commence 1Q 2019.
AM833
Obesity

Latest News

  1. Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
  2. Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
  3. Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
  4. Seattle Genetics' Adcetris Gets EC Nod for Label Expansion
  5. Market Trends Toward New Normal in GameStop, Novo Nordisk A/S, Ferroglobe, PC Connection, Nanometrics, and Anavex Life Sciences — Emerging Consolidated Expectations, Analyst Ratings
  6. Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth
  7. Novo Nordisk Is on the Upswing -- for Now
  8. Sanofi's Myeloma Candidate Meets Goal in Phase III Study
  9. Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer
  10. Novo Nordisk (NVO) Q4 2018 Earnings Conference Call Transcript
  11. Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates
  12. [$$] Danish Drugmaker Expects Higher Working Capital as Brexit Looms
  13. Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat
  14. Novo Nordisk CEO backs ending drug industry rebate system
  15. Novo Nordisk: 4Q Earnings Snapshot
  16. Novo Nordisk's new diabetes drug, outlook lift shares
  17. Novo Nordisk CEO Applauds Trump Plan to Limit Rebates
  18. [$$] Novo Nordisk Net Profit Rise Misses Expectations